Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04368702 · ClinicalTrials.gov registry record · NA
CONFIRM: Magnetic Resonance Guided Radiation Therapy
A NA study of Bladder Cancer and Gastric Cancer, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 2
- Study locations
NCT04368702: Recruiting NA study of Bladder Cancer and Gastric Cancer, sponsored by Brigham and Women's Hospital.
NCT04368702 is a NA study of Bladder Cancer and Gastric Cancer that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 70 participants, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04368702, a NA study of Bladder Cancer and Gastric Cancer, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research is being done to determine the safety and feasibility of using a type of radiation guided by magnetic resonance imaging (MRI) and chemotherapy to treat patients with gastric and breast cancer. The name of the radiation machine involved in this study is the MRIdian Linear Accelerator.
Primary Outcome
Master feasibility study evaluating MR-image guided radiation. Feasibility is defined as Enrolling patients and delivering MR-image guided radiation on the MR Linac
Conditions Studied
Interventions
- RADIATION Viewray MRIdian® Linac
Study Locations (2)
Massachusetts
- Brigham & Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2021-05-01 |
| Est. Completion | 2029-06-18 |
| Phase | NA |
What NCT04368702 shows while recruiting
NCT04368702 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower).
The record links to 6 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which Viewray MRIdian® Linac is the first listed.
NCT04368702 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04368702 about?
NCT04368702 is a clinical study titled "CONFIRM: Magnetic Resonance Guided Radiation Therapy". This research is being done to determine the safety and feasibility of using a type of radiation guided by magnetic resonance imaging (MRI) and chemotherapy to treat patients with gastric and breast cancer. The name of the radiation machine involved in this study is the MRIdian Linear Accelerator.
What is the current status of trial NCT04368702?
This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2021-05-01. Estimated completion is 2029-06-18.
What conditions does trial NCT04368702 study?
This clinical trial studies the following conditions: Bladder Cancer, Gastric Cancer, Mantle Cell Lymphoma, Invasive Breast Cancer, Larynx Cancer.
What interventions are being tested in trial NCT04368702?
The interventions under investigation include: Viewray MRIdian® Linac (RADIATION).
Who is sponsoring clinical trial NCT04368702?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04368702 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04368702's enrollment target sits among peer trials
70 99th of 175 higher than 75 of 175 other Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
RECRUITING · NA
-
Comprehensive Geriatric Assessment (Tests) for Bladder Cancer Participants Undergoing Radical Cystectomy
RECRUITING · NA
-
Bladder Cancer Screening Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI